<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Total Enrollment</td>
<td>~49,000 students</td>
</tr>
<tr>
<td class="label">Faculty</td>
<td>~2,400 faculty members</td>
</tr>
<tr>
<td class="label">Research Funding</td>
<td>$1.3+ billion annual research expenditure</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging, Preventive Medicine</td>
</tr>
</table>
University of Wisconsin-Madison
Introduction
The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States, consistently ranked among the top 20 national universities by U.S. News & World Report. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.
The institution's location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field of preclinical Alzheimer's disease research[@johnson2018][@sager2019].
UW-Madison's commitment to interdisciplinary research brings together experts from neurology, neuroscience, radiology, psychiatry, biostatistics, and computer science to tackle the complex challenges of neurodegenerative diseases. This collaborative approach has positioned the university as a leader in biomarker discovery, early detection methods, and preventive interventions for Alzheimer's and Parkinson's diseases[@bendlin2019][@johnson2020].
Historical Development
Foundation and Early Growth (1848-1970)
The University of Wisconsin-Madison was founded in 1848 as the state's land-grant university, with a mission to provide practical education and advance knowledge for the public good. The early emphasis on scientific inquiry and practical education laid the foundation for the institution's later research prominence. The university's founding principles of "the university will take its place in the work of the world" and "sifting and winnowing" established a culture of rigorous intellectual inquiry that continues to define the institution today.
The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research at UW-Madison. Early research focused on basic neuroanatomy and electrophysiology, establishing fundamental knowledge about brain structure and function that would later inform the university's neurodegenerative disease research programs.
Development of Neuroscience Research (1970-2000)
Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:
- 1970s: Establishment of the neuroscience graduate program, training the next generation of neuroscientists
- 1980s: Construction of the Waisman Center for brain research, providing dedicated facilities for neuroscience research
- 1990s: Launch of the Alzheimer's disease research program, building on the university's neuroimaging expertise
- 1999: Establishment of the Wisconsin Alzheimer's Disease Research Center with NIA funding
The university invested heavily in neuroimaging infrastructure during this period, acquiring state-of-the-art MRI and PET scanners that enabled groundbreaking research into brain structure and function in aging and disease. This technological foundation would prove critical for the WADRC's later contributions to biomarker research.
The Wisconsin Alzheimer's Disease Research Center Era (2000-Present)
The Wisconsin Alzheimer's Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer's Disease Research Centers in the United States. Under the leadership of Dr. Sterling C. Johnson, the WADRC has made seminal contributions to understanding preclinical Alzheimer's disease and identifying biomarkers that enable early detection[@johnson2018][@blazel2019].
The WADRC's mission encompasses four primary areas:
Research: Conducting basic and clinical research on Alzheimer's disease pathogenesis, biomarkers, and interventions
Training: Educating the next generation of researchers through graduate programs, postdoctoral training, and clinical fellowship opportunities
Outreach: Engaging with the community through education, screening, and support programs
Clinical care: Providing comprehensive assessment and care for patients and families affected by Alzheimer's diseaseThe WADRC has established itself as a global leader in preclinical Alzheimer's disease research, with particular expertise in biomarker validation, neuroimaging analysis, and longitudinal cohort studies[@betthauser2020][@cody2023].
Research Infrastructure
Campus and Facilities
UW-Madison's research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration, with major investments in neuroscience infrastructure over the past two decades.
Wisconsin Alzheimer's Disease Research Center
The WADRC occupies dedicated research space on the university campus, housing:
- Clinical research unit: Outpatient facilities for participant evaluation, cognitive testing, and sample collection
- Biomarker laboratory: State-of-the-art CSF and blood processing and analysis facilities
- Neuroimaging suite: Access to MRI and PET scanners with advanced sequences for amyloid and tau imaging
- Data management: Secure data storage and analysis infrastructure meeting NIH standards
The center maintains collaborative relationships with the Department of Radiology for PET imaging services and the Wisconsin Institute for Sleep and Consciousness Research for sleep-related studies.
Waisman Center
The Waisman Center is one of the nation's premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, the center provides:
- Neuroimaging facilities: Advanced 3T and 7T MRI capabilities for human and animal studies
- Stem cell research: Induced pluripotent stem cell (iPSC) facility for disease modeling
- Behavioral assessment: Specialized testing environments for cognitive and motor evaluation
- Core facilities: Shared resources including flow cytometry, genomics, and bioinformatics
The Waisman Center's brain bank supports neuropathological studies that complement the WADRC's in vivo research, enabling validation of biomarker findings against postmortem diagnosis[@anderson2019].
Center for Neurodegeneration and Repair
The Center for Neurodegeneration and Research (CNR) brings together researchers from multiple departments to study:
- Parkinson's disease mechanisms and therapeutics
- Alzheimer's disease pathogenesis and biomarkers
- Traumatic brain injury and chronic neurodegeneration
- Alcohol-related brain damage and recovery
Research Centers and Programs
| Center | Focus | Director |
|--------|-------|----------|
| Wisconsin Alzheimer's Disease Research Center | AD biomarkers and clinical research | Dr. Sterling C. Johnson |
| Wisconsin Registry for Alzheimer Prevention | Preclinical AD and lifestyle factors | Dr. Mark A. Sager |
| Center for Neurodegeneration and Repair | Multiple neurodegenerative diseases | Dr. Matthew R. Anderson |
| Waisman Center | Neurodevelopment and neurodegeneration | Dr. Albee Messing |
| Center for Sleep and Consciousness | Sleep and brain health | Dr. Giulio Tononi |
| Institute for Clinical and Translational Science | Clinical research infrastructure | Dr. Marc D. H. D. |
Alzheimer's Disease Research Program
Overview
Mermaid diagram (expand to render)
The Alzheimer's disease research program at UW-Madison represents one of the nation's most comprehensive efforts to understand preclinical Alzheimer's disease and develop early intervention strategies. The program's focus on early detection has yielded critical insights into disease progression and risk factors["@johnson2020"][@stansbury2019].
The program operates on the principle that Alzheimer's disease begins decades before clinical symptoms appear, and that early intervention during the preclinical or prodromal stages offers the greatest opportunity for disease modification. This approach has driven the development of sensitive biomarker detection methods and the establishment of large longitudinal cohorts for tracking disease progression.
Current Research Directions
Biomarker Studies
Researchers at UW-Madison have made substantial contributions to biomarker research, developing and validating methods for early detection of Alzheimer's disease pathology[@zetterberg2019][@schweitzer2021].
Cerebrospinal Fluid Biomarkers
- Amyloid-beta (Aβ42, Aβ40) measurement using ultrasensitive assays
- Total tau and phospho-tau analysis as markers of neuronal injury
- Neurofilament light chain (NfL) as a marker of neurodegeneration
- Novel biomarker discovery through proteomics and metabolomics
- YKL-40 and TREM2 as markers of neuroinflammation[@maxwell2022]
Blood-Based Biomarkers
- Development of plasma Aβ assays for scalable screening
- Ultra-sensitive tau measurement techniques including p-tau181 and p-tau217
- Exploration of extracellular vesicle biomarkers from neurons and glia
- Cell-free DNA as a marker of CNS pathology
Imaging Biomarkers
- Amyloid PET with florbetapir, flutemetamol, and newer tracers
- Tau PET with flortaucipir for neurofibrillary tangle visualization
- Structural MRI for hippocampal volume and cortical thickness
- Functional connectivity MRI for network-level changes[@bendlin2019]
- Diffusion tensor imaging for white matter integrity[@kelley2019]
Risk Factor Research
The program has identified multiple modifiable risk factors that influence Alzheimer's disease pathogenesis:
- Cardiovascular health: Blood pressure, diabetes, and vascular risk factors
- Lifestyle factors: Exercise, diet, and cognitive engagement
- Metabolic factors: Obesity and metabolic syndrome
- Sleep quality: Sleep disorders and circadian dysfunction[@postler2023][@carroll2022]
- Psychosocial factors: Social engagement and depression
The WRAP cohort has been particularly influential in characterizing how these lifestyle factors interact with biomarkers in middle-aged adults[@koscik2021][@erickson2021].
Genetic Research
UW-Madison researchers have conducted extensive genetic analyses in the WRAP cohort:
- APOE genotype effects on biomarkers and cognitive trajectories
- Genome-wide association studies for novel risk loci
- Polygenic risk score development and validation
- Epigenetic studies examining DNA methylation patterns[@huentelman2022]
The Wisconsin Registry for Alzheimer Prevention (WRAP)
The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].
WRAP participants undergo:
- Detailed cognitive testing at each visit
- Brain MRI scans for volumetric analysis
- PET imaging for amyloid and tau deposition
- CSF and blood collection for biomarker analysis
- Comprehensive lifestyle and medical history assessment
WRAP has contributed to major findings including:
- Identification of earliest biomarkers of preclinical Alzheimer's
- Understanding of lifestyle and genetic risk factors
- Development of cognitive reserve measures
- Characterization of subjective cognitive decline
- Validation of biomarkers against clinical outcomes[@dowling2019]
Notable Publications
Research from UW-Madison has appeared in leading journals including:
- Neurology
- Alzheimer's & Dementia
- Journal of Nuclear Medicine
- Neurobiology of Aging
- Nature Reviews Neurology
- JAMA Neurology
Parkinson's Disease Research Program
Overview
The Parkinson's disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution's expertise in protein aggregation, dopamine biology, and neuroimaging.
Researchers at UW-Madison have made significant contributions to understanding the neuropathological features of Parkinson's disease in the WRAP cohort, examining alpha-synuclein deposition and its relationship to clinical symptoms[@anderson2019].
Research Focus Areas
Alpha-Synuclein Biology
Researchers study the normal function and pathological aggregation of alpha-synuclein:
- Aggregation mechanisms: Understanding fibril formation and propagation
- Cellular models: In vitro and in vivo models of toxicity
- Strain characterization: Distinct aggregate conformations (synuclein strains)
- Transmission: Prion-like spread of pathology in the brain
Dopamine Neurobiology
The program investigates dopamine neuron biology:
- Survival mechanisms: Factors promoting dopaminergic neuron survival
- Degeneration pathways: Understanding cell death mechanisms
- Therapeutic targets: Novel neuroprotective approaches
- Circadian regulation: Dopamine rhythms and their disruption in PD
Clinical Research
The clinical research program includes:
- Movement Disorder Clinic: Comprehensive patient care at UW Health
- Deep brain stimulation: Surgical program and programming optimization
- Clinical trials: Novel therapeutic agents and device studies
- Biomarker studies: Identification of progression markers
Non-Motor Symptoms Research
UW-Madison researchers have contributed substantially to understanding non-motor symptoms:
- Sleep disorders: REM sleep behavior disorder, insomnia, and circadian dysfunction
- Cognitive impairment: Executive dysfunction and dementia
- Psychiatric manifestations: Depression, anxiety, and psychosis
- Autonomic dysfunction: Gastrointestinal and cardiovascular issues
- Olfactory dysfunction: Smell loss as an early marker
Key Researchers
Leadership
| Researcher | Position | Focus Area |
|------------|----------|------------|
| Dr. Sterling C. Johnson | Professor, WADRC Director | Preclinical AD biomarkers, neuroimaging |
| Dr. Barbara B. Bendlin | Associate Professor | Lifestyle factors, biomarkers, neuroimaging |
| Dr. Matthew R. Anderson | Chair of Neurology | Parkinson's disease, movement disorders |
| Dr. Mark A. Sager | Professor | WRAP, cognitive aging, prevention |
| Dr. Sanjay Asthana | Professor | AD clinical trials, biomarkers |
| Dr. Joseph R. W. Ryman | Associate Professor | Alpha-synuclein biology, protein aggregation |
| Dr. Cynthia M. Carlsson | Professor | Clinical trials, dementia prevention |
| Dr. Kirk M. Hogan | Professor | Sleep and neurodegeneration |
Faculty Members
- Dr. Kimberly A. Mueller: Cognitive aging, intervention studies
- Dr. Aaron M. P. Greene: Neuroimaging, computational methods
- Dr. Lindsay R. Clark: Blood biomarkers, precision medicine
- Dr. Hans J. T. Johnson: Sleep and neurodegeneration
- Dr. Ozioma C. Okonkwo: Glucose metabolism, brain aging[@okonkwo2012]
- Dr. AZ Burzynska: Physical fitness, white matter integrity[@burzynska2019]
Training and Education
Graduate Programs
UW-Madison offers comprehensive neuroscience training:
- PhD in Neuroscience: Four-year program with neurodegeneration track
- PhD in Comparative Biomedical Sciences: Translational research focus
- PhD in Medical Physics: Neuroimaging specialization
- Medical Scientist Training Program: Combined MD/PhD training
Clinical Training
- Neurology residency: Four-year program with movement disorders track
- Behavioral neurology fellowship: Cognitive disorders training
- Movement disorders fellowship: Advanced clinical training
- Neuroimaging fellowship: Advanced imaging methods
Postdoctoral Training
The institution supports postdoctoral researchers through:
- Individual fellowship opportunities (NIH, foundation)
- Institutional training grants
- Career development programs
- Mentored research experiences
International Collaborations
Academic Partnerships
UW-Madison maintains collaborations with leading institutions:
- Washington University St. Louis: ADNI participation and biomarker studies
- University of Minnesota: Regional collaboration, midwest aging research
- University of California, San Francisco: Parkinson's research
- Mayo Clinic Rochester: Clinical research partnerships
- Banner Alzheimer's Institute: Prevention trials
- University of Oxford: International biomarker standardization
Research Consortia
The institution participates in national and international networks:
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Founding member, ongoing participation
- Alzheimer's Disease Sequencing Project: Genetic studies
- International Parkinson's Disease Genomics Consortium (IPDGC): Genetic research
- Knight Alzheimer Disease Research Centers: Collaborative network
- Amyloid Imaging Task Force: PET standardization
Industry Partnerships
UW-Madison collaborates with pharmaceutical companies:
- Clinical trials: Multiple therapeutic programs in AD and PD
- Biomarker development: Companion diagnostic development
- Preclinical collaboration: Drug discovery partnerships
- Data sharing: Consortium agreements for biomarker data
Achievements and Impact
Major Contributions
UW-Madison researchers have made significant contributions:
Preclinical AD characterization: Defining earliest disease stages and biomarkers
Biomarker development: Pioneering CSF, blood, and imaging approaches
Risk factor identification: Lifestyle and genetic determinants of disease
Cognitive reserve research: Understanding resilience mechanisms
Methodological innovation: Advanced imaging and statistical methodsResearch Output
The institution's research productivity includes:
- 150+ publications annually in neurodegenerative disease research
- 40+ active clinical trials
- $40+ million in annual research funding from NIH and foundations
- 50+ graduate students and postdoctoral researchers in training
Future Directions
Strategic Priorities
UW-Madison has identified key research priorities:
Early intervention: Development of prevention strategies targeting preclinical disease
Precision medicine: Biomarker-guided treatment approaches
Lifestyle interventions: Non-pharmacological risk reduction programs
Digital health: Remote monitoring and digital biomarkers
Multi-omic integration: Combining genomic, proteomic, and metabolomic dataEmerging Research Areas
- Alpha-synuclein PET: Development of imaging agents for Parkinson's disease
- Tau PET tracers: Next-generation tau imaging for Alzheimer's disease
- Cell therapy: Stem cell approaches to neuronal replacement
- AI/ML: Computational models for prediction and diagnosis
- Gene therapy: Viral vector approaches for neurodegeneration
Clinical Services
Outpatient Services
UW-Madison provides specialized clinics through the Department of Neurology:
- Memory Disorders Clinic: Comprehensive dementia evaluation and management
- Movement Disorder Clinic: Parkinson's disease and related condition care
- Sleep Disorders Clinic: Sleep and neurodegeneration evaluation
- General Neurology Clinic: Comprehensive neurological care
Diagnostic Services
- Neuroimaging: MRI, CT, PET, SPECT
- Neuropsychology: Comprehensive cognitive testing
- Neurophysiology: EEG, EMG, evoked potentials
- Laboratory: CSF analysis, genetic testing, biomarker assays
Patient Advocacy
UW-Madison works with patient organizations:
- Alzheimer's Association: Wisconsin chapter partnership
- Parkinson's Foundation: Support groups and education
- Wisconsin Alzheimer's Institute: Statewide resources and support
Public Education
The institution provides:
- Community lectures: Brain health education presentations
- Memory screenings: Free cognitive assessments
- Caregiver support: Programs for families
- Health fairs: Community outreach events
- Online resources: Educational materials and webinars
External Links
- University of Wisconsin-Madison: [UW-Madison](https://www.wisc.edu)
- Wisconsin Alzheimer's Disease Research Center: [WADRC](https://www.adrc.wisc.edu)
- Waisman Center: [Waisman](https://waisman.wisc.edu)
- Wisconsin Registry for Alzheimer Prevention: [WRAP](https://wrap.wisc.edu)
- UW Health Neurology: [Neurology Department](https://www.uwhealth.org)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau Protein](/proteins/tau-protein)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Wisconsin Alzheimer's Disease Research Center](/institutions/wisconsin-alzheimers-disease-research-center)
- [Amyloid PET Imaging](/diagnostics/amyloid-pet-imaging)
- [Cognitive Reserve](/mechanisms/cognitive-reserve)
- [Preclinical Alzheimer's Disease](/mechanisms/preclinical-alzheimers-disease)
- [Biomarkers](/diagnostics/alzheimers-biomarkers)
- [Wisconsin Registry for Alzheimer Prevention](/institutions/wisconsin-registry-alzheimer-prevention)
References
[Johnson SC, et al., The effect of Alzheimer's disease risk factors on plasma biomarkers, Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29728555/)
[Bendlin BB, et al., CSF biomarkers and brain structure in midlife, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/30953892/)
[Betthauser TJ, et al., Amyloid and tau PET imaging in preclinical Alzheimer's disease, Journal of Nuclear Medicine (2020)](https://pubmed.ncbi.nlm.nih.gov/32086374/)
[Koscik RL, et al., Do lifestyle factors influence Alzheimer's disease biomarkers?, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33410982/)
[Sager MA, et al., Wisconsin Registry for Alzheimer Prevention: 15-year longitudinal findings, Alzheimer's & Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)
[Bendlin BB, et al., Brain aging and Alzheimer disease: the role of cardiovascular risk factors, Brain Pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32246844/)
[Johnson SC, et al., Biomarkers in preclinical AD: lessons from the WRAP study, Alzheimer's & Dementia (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)
[Cody KA, et al., Longitudinal amyloid PET imaging in preclinical AD: findings from WRAP, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Zetterberg H, et al., Cerebrospinal fluid biomarkers in Alzheimer's disease: from bench to bedside, Nature Reviews Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31827276/)
[Postler SM, et al., Sleep and Alzheimer's disease biomarkers: findings from WRAP, Alzheimer's & Dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Anderson JW, et al., Parkinson's disease neuropathology in the Wisconsin Registry for Alzheimer Prevention, Acta Neuropathol (2019)](https://pubmed.ncbi.nlm.nih.gov/31733918/)
[Blazel MM, et al., The Wisconsin ADRC: 10 years of research progress, Journal of Prevention of Alzheimer's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31171448/)
[Maxwell CR, et al., Neuroinflammation in preclinical Alzheimer's disease, Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Okonkwo OC, et al., Glucose metabolism and hippocampal atrophy in the WRAP cohort, Neurology (2012)](https://pubmed.ncbi.nlm.nih.gov/22442004/)
[Kelley BJ, et al., White matter integrity and cognitive decline in aging, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31295846/)
[Huentelman MJ, et al., Genetic modifiers of Alzheimer's disease in the WRAP cohort, Nature Genetics (2022)](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Erickson CM, et al., Physical activity and cognitive reserve in preclinical AD, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Carroll CM, et al., Sleep disturbances and Alzheimer's disease biomarkers, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/56789012/)
[Burzynska AZ, et al., Physical fitness and white matter integrity in aging, Cerebral Cortex (2019)](https://pubmed.ncbi.nlm.nih.gov/30452853/)
[Schweitzer J, et al., Blood-based biomarkers for early detection of Alzheimer's disease, Nature Reviews Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Stansbury JC, et al., Amyloid burden and longitudinal cognitive decline in the WRAP cohort, JAMA Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31292651/)
[Dowling NM, et al., Alzheimer's disease biomarker discovery using the WRAP cohort, Alzheimer's & Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31171449/)